共查询到20条相似文献,搜索用时 312 毫秒
1.
IgG subclass levels of sera from 105 patients with systemic lupus erythematosus (SLE) were determined by immunonephelometric
assay. Patients were divided into two groups according to clinical activity of the disease: active disease and remission.
Forty-five normal controls were also measured. We found a significant increase of IgG1 (p = 0.000), IgG2 (p = 0.000), and IgG3 (p = 0.000) in SLE sera, while IgG4 (p = 0.494) values did not differ significantly from those of controls. When patients were divided according to clinical activity,
decrease of IgG3 concentration was observed in the patients in remission. In contrast, the concentrations of IgG1, IgG2, and
IgG4 subclass were similar between the two groups (p > 0.05). Our data suggest that differential increase of IgG subclasses during the course of SLE may be of relevance to the
pathogenesis of the disease. 相似文献
2.
We evaluated the significance of platelet activation in patients with rheumatoid arthritis (RA). The expression of CD62P and
CD63 by platelets was determined using flow cytometry in 18 active RA patients, 10 remission RA and 15 normal controls. Meanwhile,
the erythrocyte sedimentation rate (ESR) and C-reactive protein was also determined in all groups. The expression of CD62P
in active RA patients (11.88 ± 2.47%) was significantly higher than that in remission RA group (2.85 ± 1.60%; P < 0.01) and control group (2.78 ± 1.04%; P < 0.01). The expression of CD63 in active RA patients (9.90 ± 3.02%) was significantly higher than that in remission RA group
(4.11 ± 2.00%; P < 0.01) and control group (4.13 ± 1.85%; P < 0.01). The level of CRP (54.33 ± 23.35 mg/l) and ESR (86.06 ± 33.67 mm/h) in active RA patients was higher than that in
remission RA group (2.55 ± 1.01 mg/l, 14.70 ± 4.57 mm/h; P < 0.01 for both) and normal control group (3.21 ± 2.18 mg/l, 12.25 ± 5.05 mm/h; P < 0.01 for both). There was a positive correlation between CD62P and ESR (r = 0.5224, P < 0.01) and also a positive correlation between CD62P and CRP (r = 0.7048, P < 0.01) as well as between CD63 and ESR (r = 0.4476, P < 0.05) but no correlation between CD63 and CRP. Platelet activation may be a sign of RA exacerbation. 相似文献
3.
Asfour IA Fayek MH El-Kourashy SA Youssef SR El-Gohary GM Mohamed OF 《Annals of hematology》2008,87(3):213-221
Telomerase is activated in most tumors, but suppressed in normal human somatic cells. Current evidence indicates that telomerase
reactivation is a critical step in carcinogenesis, with a close relationship to apoptosis. The goal of this study was to investigate
the levels and relationship of telomerase activity to apoptosis and its impact on the survival of Egyptian adult acute lymphoblastic
leukemia patients. Telomerase activity was quantified by polymerase chain reaction (PCR) and detected by enzyme-linked immunosorbent
assay (ELISA), while apoptosis was measured at the single-cell level by fluorescence in situ detection using flow cytometry
in 15 control subjects and 40 acute lymphoblastic leukemia (ALL) patients at presentation. Telomerase activity in ALL patients
was negatively correlated to apoptosis [percent and mean fluorescence intensity (MFI)] (p < 0.001 for percent and p < 0.001 for MFI) and to the 4-year survival rate (p < 0.05), to which apoptosis (percent and MFI) was consequently positively correlated (p < 0.001 for percent and p < 0.05 for MFI). For telomerase, the highest positive predictive value (PPV) for mortality (93.3%) was at a cut-off value
of 13 amol/ml, while those for apoptosis (85% for percent of apoptotic cells and 90.9% for MFI) were at a cut-off of 8% and
0.19 MFI. This makes the measurement of telomerase activity in ALL patients a potential tool to predict disease with unfavorable
outcome and a candidate tumor marker. 相似文献
4.
Yu SF Cheng TT Hsu YH Lai HM Chen YC Chiu CK Lin KM Chang C Chen CJ Kang HY 《Clinical rheumatology》2007,26(12):2051-2058
We investigated the relationship between CAG and GGC repeat polymorphism of the androgen receptor (AR) gene and rheumatoid
arthritis (RA) in female patients with different disease subtypes. This case-control study enrolled 215 women in three groups:
RA patients refractory to standardized therapy (n = 51); RA patients at complete remission phase (n = 60); and healthy controls (n = 104). CAG and GGC repeat lengths were determined by automated fluorescence-based DNA fragment-sizing method. Demographic
data, allele lengths, allele distribution, and zygosity status of CAG/GGC repeats were assessed for the three groups. Refractory
RA patients tend to have a significantly younger onset age of RA and more elevated erythrocyte sedimentation rates than do
remission RA patients. Mean and median values of CAG and GGC repeat lengths are similar in both RA and control patients. However,
RA patients harboring any long CAG alleles with more than 23 repeats had an increased risk of a refractory course, whereas
differences in risk were not observed between these patients and RA subtypes harboring any long GGC alleles with more than
16 repeats. In addition, the homozygous frequency of CAG but not GGC alleles was lower in refractory RA than in remission
RA patients or in controls (p = 0.042). Neither CAG nor GGC repeat lengths had a significant relationship with rheumatoid factor reactivity. Our observations
indicate that short CAG repeats of the AR gene with higher transactivation activity may have protective effects against refractory
course of RA development and that homozygous frequency of CAG alleles may be involved in the disease remission subtype. In
contrast, lack of association of GGC polymorphism and RA was also observed. Together, these data imply that CAG but not GGC
alleles in the AR polymorphism may play an important role in modulating the disease pattern of RA among Taiwanese women. 相似文献
5.
Michael J. Silverberg Wendy Leyden Charles P. QuesenberryJr. Michael A. Horberg 《Journal of general internal medicine》2009,24(9):1065-1072
BACKGROUND Prior studies evaluating racial/ethnic differences in responses to antiretroviral therapy (ART) among HIV-infected patients
have not adequately accounted for many potential confounders, and few have included Hispanic patients.
OBJECTIVE To identify racial/ethnic differences in ART adherence, and risk of AIDS and death after ART initiation for HIV patients with
similar access to care.
DESIGN Retrospective cohort study.
PARTICIPANTS 4,686 HIV-infected patients (66% White, 20% Black, and 14% Hispanic) initiating ART and who were enrolled in an integrated
healthcare system.
MEASUREMENTS Main outcomes evaluated were ART adherence, new AIDS clinical events, and all-cause mortality. The potential confounding effects
of demographics, socioeconomic status, ART parameters, HIV disease stage, and other clinical parameters were considered in
multivariable models.
RESULTS Adjusted mean adherence levels were higher among White (70.1%; ref) compared with Black (64.2%; P < 0.001) and Hispanic patients (65.2%; P < 0.001). Adjusted hazard ratios (HR) for the risk of new AIDS events (White patients as reference) were 1.3 (P = 0.09) for Black and 0.9 (P = 0.64) for Hispanic patients. The adjusted HR for AIDS comparing Hispanic to Black patients was 0.7 (P = 0.11). Hispanic patients had fewer deaths compared with other racial/ethnic groups, particularly cancer and cardiovascular-related.
However, adjusted HRs for death were 1.2 (P = 0.37) and 0.9 (P = 0.62) for Black and Hispanic patients, respectively, compared with White patients and 0.9 (P = 0.63) for Hispanic compared with Black patients. Adjustment for adherence did not change inferences for AIDS or death.
CONCLUSIONS In the setting of similar access to care, we did not observe a disparity for the risk of clinical events for racial/ethnic
minorities, despite lower ART adherence.
This material was presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention,
Sydney, Australia, July 22–25, 2007 (#WEPEB107). This research was supported by a Community Benefit grant from Kaiser Permanente
Northern California and grant number K01AI071725 from the NIAID. 相似文献
6.
The objective of this study was to explore the significance of platelet activation in patients with ankylosing spondylitis
(AS). Thirty-five AS patients and 15 normal controls were selected from November 2005 to October 2006. The number of CD62P-
and CD63-positive cells were detected by flow cytometry. At the same time, the erythrocyte sedimentation rate (ESR), platelet
count (PLT) and C-reactive protein (CRP) were determined in both groups. The percentage of CD62P-positive cell in AS patients
(13.60 ± 7.64%) was significantly higher than that in control group (2.78 ± 1.04%; P < 0.01). The percentage of CD63-positive cell in AS patients (6.92 ± 4.16%) was significantly higher than that in control
group (4.13 ± 1.85%; P < 0.05). The levels of CRP (20.18 ± 23.17 mg/l), PLT (259.54 ± 102.59 × 109/l) and ESR (36.86 ± 31.23 mm/h) in AS patients were higher than those in normal controls, respectively (3.21 ± 2.18 mg/l,
P < 0.01; 197.00 ± 55.70 × 109/l, P < 0.01; 12.25 ± 5.05 mm/h, P < 0.05). Platelet activation may be a sign of AS exacerbation. 相似文献
7.
Yelda Bilginer Rezan Topaloglu Ayfer Alikasifoglu Nazlı Kara Nesrin Besbas Seza Ozen Aysin Bakkaloglu 《Clinical rheumatology》2010,29(3):309-314
The aim of our study was to evaluate the neuroendocrine system in patients with juvenile idiopathic arthritis (JIA) regarding
the activity of disease. Twenty-one JIA patients (mean age ± standard deviation 10.5 ± 4.1 years) were included. None of the
patients was taking steroids or antitumor necrosis factor-α therapy during this study. Ten healthy volunteers and ten volunteers
with upper respiratory tract infection composed the control groups. Furthermore, ten of the 21 JIA patients were also evaluated
during the remission period. Erythrocyte sedimentation rate, C-reactive protein, adrenocorticotropic hormone (ACTH), cortisol,
prolactin, insulin-like growth factor-1 (IGF-1), insulin-like growth factor-binding protein 3, free T3, free T4, thyroid-stimulating
hormone, interleukin-6 (IL-6) levels, and 24-h urinary cortisol were evaluated both during the active period and remission.
The median levels of ACTH and cortisol at 08:00 a.m. were significantly lower in patients with active JIA than patients in
remission period and the control groups (p < 0.05). Furthermore, the median level of urine cortisol in active JIA patients was significantly lower than remission period
and control groups (p < 0.05). The median level of IGF-1 was significantly lower in active patients than that of remission (p < 0.05). The median level of IL-6 in active JIA patients was significantly higher than those in remission and control groups
(p < 0.05). Our preliminary study suggested that impaired secretion of adenohypophyseal hormones and distorted bilateral interactions
between the immune and endocrine systems in JIA. Further studies are needed to clarify the consequences of the impaired hormone
secretion in JIA. 相似文献
8.
Background We histopathologically examined Lens culinaris agglutinin-reactive α-fetoprotein (AFP-L3)-positive hepatocellular carcinoma (HCC) and protein induced by vitamin K absence
(PIVKA) II-positive HCC to clarify the efficacy of these markers for predicting a poor prognosis.
Methods Serum AFP-L3 and PIVKA II was measured in 110 HCC patients. AFP-L3 was measured by lectin-affinity electrophoresis coupled
with antibody-affinity blotting, and PIVKA II by using a high-sensitivity kit. The growth type, capsule formation, capsule
infiltration, portal vein invasion, intrahepatic metastasis and histological tumor grade were evaluated pathologically.
Results Thirty-eight (35%) HCC patients were AFP-L3-positive, and 63 (57%) were PIVKA II-positive. In AFP-L3-positive HCC, the frequencies
of an infiltrative growth type (positive : negative = 66% : 42%, P = 0.027) and a poorly differentiated type (positive : negative = 32% : 6%, P < 0.001) were significantly higher than in AFP-L3-negative HCC. In PIVKA II-positive HCC, the frequencies of an infiltrative
growth type (positive : negative = 62% : 28%, P < 0.001), vascular invasion (positive : negative = 63% : 26%, P < 0.001), and intrahepatic metastasis (positive : negative = 38% : 4%, P < 0.001) were significantly higher than in PIVKA II-negative HCC. In both AFP-L3- and PIVKA II-positive HCC, the frequency
of a poorly differentiated growth type was significantly higher than in HCC positive for either AFP-L3 or PIVKA II or HCC
negative for both AFP-L3 and PIVKA II (both positive : either positive : both negative = 37% : 12% : 0%; P = 0.014, P < 0.001, respectively).
Conclusions AFP-L3 was related to progression from moderately differentiated to poorly differentiated HCC, whereas PIVKA II was more specific
to vascular invasion. PIVKA II is therefore likely to be a useful indicator of vascular invasion. 相似文献
9.
Levent Ozgonenel Esra Cetin Sule Tutun Pinar Tonbaklar Hale Aral Guvenc Guvenen 《Clinical rheumatology》2010,29(5):473-477
Vascular endothelial growth factor (VEGF) is known to be involved in the pathogenesis of rheumatoid arthritis (RA). In order
to elucidate the association between VEGF levels and RA disease activity, VEGF concentrations were measured in RA patients
at different phases and severity levels. Thirty-eight healthy subjects and 40 patients with RA were prospectively included
in the study. Subjects were further categorized into four subgroups (high, moderate, low, or remission) using the disease
activity score-28 (DAS28) scoring system. VEGF levels were significantly higher in patients than controls (p < 0.001). VEGF levels differed significantly in controls, early and late-phase RA patients (p = 0.002). A significant difference was found between controls and patients with high RA disease activity scores (p < 0.0001). VEGF levels were not correlated with age (r = −0.016; p = 0.921) or sex (r = 0.209; p = 0.921). VEGF values were correlated with erythrocyte sedimentation rate (r = 0.445; p = 0.004), but was not correlated with serum rheumatoid factor levels (r = −0.130; p = 0.424) in the patient group. In conclusion, higher VEGF levels are associated with late phase and high disease activity
in RA, independent of age and sex. 相似文献
10.
We report on four cases (three women, one man, age at diagnosis 26–61 years) with severe autoimmune thrombocytopenia (AITP)
who were refractory to initial steroid therapy (n = 4), to subsequent splenectomy (n = 2), azathioprine (n = 1), and cyclosporine (n = 1). Over years they received low-dose continuous or intermittent steroid therapy. After 6 to 31 years these patients achieved
a “spontaneous” complete remission (CR) (n = 3) or partial remission (PR) (n = 1) unrelated to any specific second or third line treatment; CR/PR are sustained for 0.5+ to 9+ years. These data indicate
that spontaneous remissions may occur in AITP even after a long duration of the disease. 相似文献
11.
Scarpa M D'Incà R Basso D Ruffolo C Polese L Bertin E Luise A Frego M Plebani M Sturniolo GC D'Amico DF Angriman I 《Diseases of the colon and rectum》2007,50(6):861-869
Purpose This study was designed to assess the role of fecal lactoferrin and calprotectin as markers of intestinal inflammation in
patients with Crohn’s disease who have undergone ileocolonic resection.
Methods Sixty-three patients who had undergone ileocolonic resection for Crohn’s disease with a median follow-up of 40.5 (range, 5–102)
months were enrolled. Clinical examination and blood test were performed, and fecal lactoferrin and calprotectin levels were
dosed. The predictors for fecal lactoferrin and calprotectin levels that resulted to be significant at the univariate analyses
were included in two multiple regression analysis models.
Results The mean lactoferrin level was 21 ± 3.9 μg/g and the mean calprotectin fecal level was 247 ± 22.7 ng/ml. C-reactive protein
levels (P < 0.01), calprotectin levels (P < 0.01), and the presence of clinical recurrence (P = 0.04) resulted to be independent predictors of lactoferrin levels. Only lactoferrin levels resulted to be an independent
predictor for calprotectin fecal levels (P < 0.01).
Conclusions Crohn’s disease patients maintain high fecal levels of lactoferrin and calprotectin at long-term follow-up after resection
of the diseased bowel even in case of clinical remission. The significant correlation between the two fecal markers may be
the expression of the ongoing intestinal inflammation. Only lactoferrin significantly correlated with C-reactive protein and
showed a reliable threshold value for systemic inflammation. Lactoferrin fecal levels may be a reliable indicator for intestinal
inflammation influencing the systemic inflammatory status. The third predictor of lactoferrin fecal level was the presence
of episodes of clinical recurrence during the postoperative follow-up.
Supported in part by the MIUR grant ex 60%. 相似文献
12.
Madisch A Miehlke S Eichele O Mrwa J Bethke B Kuhlisch E Bästlein E Wilhelms G Morgner A Wigginghaus B Stolte M 《International journal of colorectal disease》2007,22(12):1445-1451
Background and aims The objective of this study was to investigate the effect of Boswellia serrata extract (BSE) on symptoms, quality of life, and histology in patients with collagenous colitis.
Materials and methods Patients with chronic diarrhea and histologically proven collagenous colitis were randomized to receive either oral BSE 400 mg
three times daily for 6 weeks or placebo. Complete colonoscopy and histology were performed before and after treatment. Clinical
symptoms and quality of life were assessed by standardized questionnaires and SF-36. The primary endpoint was the percentage
of patients with clinical remission after 6 weeks (stool frequency ≤3 soft /solid stools per day on average during the last
week). Patients of the placebo group with persistent diarrhea received open-label BSE therapy for a further 6 weeks.
Results Thirty-one patients were randomized; 26 patients were available for per-protocol-analysis. After 6 weeks, the proportion of
patients in clinical remission was higher in the BSE group than in the placebo group (per protocol 63.6%; 95%CI, 30.8–89.1
vs 26.7%, 95%CI, 7.7–55.1; p = 0.04; intention-to-treat 43.8% vs 26.7%, p = 0.25). Compared to placebo, BSE treatment had no effect on histology and quality of life. Five patients discontinued BSE
treatment prematurely. Discontinuation was due to adverse events (n = 1), unwillingness to continue (n = 3), or loss to follow-up for unknown reasons (n = 1). Seven patients received open-label BSE therapy, five of whom achieved complete remission.
Conclusions Our study suggests that BSE might be clinically effective in patients with collagenous colitis. Larger trials are clearly
necessary to establish the clinical efficacy of BSE. 相似文献
13.
Clofarabine (40 mg/m2/day × 5) and high-dose cytosine arabinoside (Ara-C, 1–2 g/m2/day × 5) were used in 10 men and 11 women, at a median age of 45 (22–62) years, with refractory (N = 4) and relapsed (N = 17) acute myeloid leukaemia, after a median of 3 (2–5) prior regimens. Grade 4 myelosuppression was observed in all cases,
with two patients dying of bacterial sepsis. Nine patients achieved a complete remission. Disease status, number of prior
therapies, and cytogenetic aberrations were not associated with the outcome. However, remission was only achieved with Ara-C
at 2 g/m2/day and not 1 g/m2/day (9/15 versus 0/4, P = 0.03). 相似文献
14.
Vela-Ojeda J García-Ruiz Esparza MA Padilla-González Y Sánchez-Cortes E García-Chávez J Montiel-Cervantes L Reyes-Maldonado E Majluf-Cruz A Mayani H 《Annals of hematology》2009,88(1):59-66
Several prognostic factors have been recognized in patients with multiple myeloma (MM). Among the most important are: the
serum levels of β2-microglobulin, albumin, and LDH; the labeling index; and an abnormal karyotype. Patients with amyloidosis
(AL) have poor prognosis; however, little is known concerning the prognostic significance of AL associated to MM. In 201 consecutive
patients with de novo MM, we performed a fat-pad biopsy needle aspiration (FPBNA) that was stained with Congo red. Sixty eight
(34%) patients had AL and a poorer prognosis disease: lower performance status, presence of B symptoms, higher LDH and calcium
values, and worse response to chemotherapy. Cox regression model for overall survival detected three variables having independent
prognostic significance: the presence of AL (RR = 3.4, P < 0.004), serum albumin levels <3.5 g/dl (RR 3.2, p < 0.005), and patients not achieving complete remission or very good partial remission (RR 2.9, p < 0.02). In 28% of patients with de novo MM, FPBNA was useful to detect incidental amyloidosis. During follow-up, 69% of
these patients had symptoms of AL. Excluding 16 patients with obvious symptoms of AL at diagnosis, overall survival was worse
in patients who developed later symptoms of AL. MM-associated AL represents a poorer prognosis disease even in the absence
of symptoms at diagnosis, and this specific association may be considered as an independent high-risk prognostic factor. The
routine study of periumbilical fat-pad tissue should be mandatory in all patients with MM. 相似文献
15.
Walter Verbeek Bernhard Wörmann Peter Koch Carl Aul Hans-Fokke Hinrichs Leopold Balleisen Jacob M. Rowe John Bennett Detlef Haase Christa Fonatsch Anton Heinecke Thomas Büchner Wolfgang Hiddemann 《Journal of cancer research and clinical oncology》1999,125(6):369-374
A prospective, randomized, double-blind placebo-controlled trial was designed to evaluate the impact of granulocyte/macrophage-colony-stimulating
factor (GM-CSF) on the efficacy of sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy (S-HAM) in adult patients
with high-risk myelodysplastic syndromes (MDS). GM-CSF or placebo was given subcutaneously once daily at a dose of 250 μg/m2, starting 48 h prior to chemotherapy, and continued until neutrophil recovery. Owing to high toxicity and slow patient recruitement
the study was closed and unblinded after 31 patients had been enrolled; 15 were randomized to receive placebo and 16 to receive
GM-CSF. A total of 29 patients were evaluable for response; their median age was 57 years. Ten patients achieved a complete
remission (34.5%), 9 patients had persistent MDS (31%), 10 patients died within 6 weeks after the onset of treatment (early
death) (34.5%). The median remission duration was 190 days (range: 2.5–45 months). Among the 29 evaluable patients no significant
differences could be found between the two study arms regarding complete remission rate [GM-CSF: 31% (5/16) versus placebo:
38% (5/13) P = 0.45], rate of persistent MDS [GM-CSF: 25% (4/16) versus 38% (5/13) P = 0.35), early death rate [44% (7/16) versus 23% (3/13) P = 0.22] and remission duration (GM-CSF: 87 days versus placebo 221 days). Duration of granulocytopenia (median: 33 days with
GM-CSF) versus 35 days with placebo) and frequency of infectious episodes were not significantly influenced by GM-CSF. The
small number of patients finally analyzed means that no definite conclusions about the effect of GM-CSF can be reached.
Received: 3 June 1998 / Accepted: 5 January 1999 相似文献
16.
Aoki H Nakamura K Yoshimatsu Y Tsuda Y Irie M Fukuda K Hosoe N Takada N Shirai K Suzuki Y 《Digestive diseases and sciences》2007,52(6):1427-1433
Adacolumn selective granulocyte and monocyte apheresis (GMA) depletes activated leukocytes in patients with ulcerative colitis
(UC). However, this per se cannot fully explain the efficacy of GMA. We have investigated the effects of GMA on the expression
of toll-like receptors (TLRs) and plasma interleukin-8 (IL-8). Twenty-two patients with clinical activity index (CAI) of 5–17,
15 with total colitis and 7 with left-sided colitis, were included. Each patient could receive up to 10 GMA sessions, at 1
or 2 sessions per week. GMA was added to the patients’ ongoing medication following a relapse or worsening UC, but no additional
medication was given. Further, at entry and pre-GMA, blood samples were taken for full blood cell count, expression of TLRs
on leukocytes, and plasma IL-8. Seventy-five percent of patients achieved remission after the 10th session (CAI, ≤4; P < 0.005) and there was a marked fall in C-reactive protein (P < 0.01), plasma IL-8 (P < 0.001), and granulocytes (P < 0.05) but an increase in lymphocytes (P < 0.05). The expression of TLR2 on granulocytes was down-modulated (P < 0.05) together with suppression of inflammatory cytokines produced by peripheral blood leukocytes. In conclusion, GMA appears
to be an effective adjunct therapy to induce remission in the majority of patients, who are then spared from excess drug therapy.
The procedure is associated with sustained immunomodulation. Control studies should strengthen these findings. 相似文献
17.
Anastasios Chatzitolios Ioannis Venizelos Gregory Tripsiannis George Anastassopoulos Nikolaos Papadopoulos 《Annals of hematology》2010,89(9):889-896
Apoptosis-related proteins play an important role in lymphoma cell death during chemotherapy. In our study, we investigated
the prognostic significance of CD95, BCL2, and P53 expression in extranodal non-Hodgkin’s lymphoma (NHL). We examined 71 patients
with extranodal NHL [45 diffuse large B-cell lymphomas (DLBCLs) and 26 mucosa-associated lymphoid tissue lymphomas (MALTLs)],
35 male and 36 female, with a median age of 65.8 years. The most common site of origin was the stomach (N = 31). Paraffin-embedded specimens were analyzed immunohistochemically for CD95, BCL2, and P53 expression. Multivariate analysis
revealed that in DLBCLs, positive CD95 and negative BCL2 expression were independent prognostic factors for overall survival.
We reached the same conclusion for MALTLs, with positive CD95 and negative P53 expression. In DLBCLs, the 5-year overall survival
rate was 71.5% for the CD95-positive cases and 35% for the CD95-negative cases (p = 0.004) and the 5-year overall survival was significantly better in BCL2-negative cases (70.8%) when compared to BCL2-positive
cases (37%; p = 0.009). In MALTLs, the 5-year overall survival rate for the CD95-positive and CD95-negative groups was 89.5% and 42.9%,
respectively (p = 0.004) and the 5-year overall survival rate was 50% for the P53-positive cases and 88.9% for the P53-negative cases (p = 0.016). In conclusion, positive CD95 expression proved to be a good prognostic factor of overall survival in both extranodal
DLBCLs and MALTLs. In contrast, positive expression of BCL2 and P53 was found to be unfavorably associated with survival in
extranodal DLBCLs and MALTLs, respectively. 相似文献
18.
Impact of Tumor Location on Nodal Evaluation for Colon Cancer 总被引:1,自引:0,他引:1
Bilimoria KY Palis B Stewart AK Bentrem DJ Freel AC Sigurdson ER Talamonti MS Ko CY 《Diseases of the colon and rectum》2008,51(2):154-161
Purpose Adequate lymph node evaluation is important to stage colon cancers and make adjuvant treatment decisions. Studies have demonstrated
improved survival when ≥ 12 nodes are examined. Our objective was to assess differences in the adequacy of nodal evaluation
for right vs. left colon cancers.
Methods From the National Cancer Data Base (1998–2004), 142,009 N0M0 colon cancer patients were identified. Logistic regression was
used to evaluate the number of nodes examined for right vs. left colectomies. Multivariable modeling was used to determine the impact of examining ≥ 12 nodes on survival.
Results Of 142,009 patients, 79,444 (56 percent) had right colectomies, and 62,565 (44 percent) patients had left colectomies. More
nodes were examined during right colectomies than left (median 12 vs. 8, P < 0.0001). When adjusted for patient, tumor, and hospital factors, patients undergoing left colectomy were less likely to
have ≥ 12 nodes identified (P < 0.0001). Patients were more likely to have ≥ 12 nodes identified for right and left colon cancers at high-volume hospitals.
Survival was better with examination of ≥ 12 nodes for right and left colon cancers (P < 0.0001).
Conclusions Evaluating ≥ 12 nodes for right and left colon cancers is a feasible, clinically relevant, and modifiable factor that will
likely improve patient outcomes.
Presented in part at the meeting of The American Society of Colon and Rectal Surgeons, St. Louis, Missouri, June 2 to 7, 2007.
Supported by a grant from the National Cancer Institute. Dr. Bilimoria is supported by the American College of Surgeons, Clinical
Scholars in Residence program, and a research grant from the Department of Surgery, Feinberg School of Medicine, Northwestern
University. 相似文献
19.
Adhesion molecules in chronic ulcerative colitis 总被引:3,自引:0,他引:3
Gulubova MV Manolova IM Vlaykova TI Prodanova M Jovchev JP 《International journal of colorectal disease》2007,22(6):581-589
Background and aims The adhesion molecule expression in colonic mucosa is pivotal for transition from quiescent to active stage of ulcerative
colitis (UC). The aim of the present study is to reveal the adhesion molecule profile of colonic mucosa in the active stage
of UC and in remission.
Materials and methods Biopsy specimens obtained from 14 patients with UC (seven with active disease and seven with UC in remission) and from seven
controls were used. Immunohistochemistry was performed with antibodies against ICAM-1, VCAM-1, E-selectin, LFA-1, Mac-1, and
VLA-4.
Results In controls, slight ICAM-1 positivity was observed on thety endothelium of blood vessels of the mucosal and submucosal layer
and only single ICAM-1-, Mac-1-, and LFA-1-positive cells were found. In all patients with UC, the endothelium of venules
in the edematous mucosal and submucosal layers was ICAM-1-, VCAM-1-, and E-selectin-positive. Numerous ICAM-1- and LFA-1-positive
and less VCAM-1-, Mac-1-, and VLA-4-positive inflammatory cells were detected in mucous layers of acute UC. In specimens of
UC in remission, the inflammatory cells positive for the studied adhesion molecules were significantly less in number in the
mucosa and submucosa (p < 0.05).
Conclusions Based on the increased expression of ICAM-1, VCAM-1, and their ligands LFA-1 and VLA-4 in patients with UC, we can conclude
that these adhesion molecules play a key role in the adherence of lymphocytes and macrophages to endothelial cells maintaining
the chronic inflammation. Presence of E-selectin on endothelial cells of venules could be a sign of relapse after remission
in UC. 相似文献
20.
Aims/hypothesis The aim of this study was to ascertain whether treatment of GAD65 autoantibody (GADA)-positive diabetic patients with alum-formulated
recombinant GAD65 (GAD-alum) is safe and does not compromise beta cell function.
Methods This Phase 2, placebo-controlled, dose-escalation clinical trial, which was randomized through a central office, was performed
in 47 GADA-positive type 2 diabetic patients, who received subcutaneous injections of GAD-alum (4 [n = 9], 20 [n = 8], 100 [n = 9] or 500 [n = 8] μg) or placebo (n = 13) at weeks 1 and 4 of the trial. Participants and caregivers were blinded to group assignments. The primary outcome was
safety as assessed by neurological tests, medications and beta cell function evaluated over 5 years, representing the end
of the trial.
Results No severe study-related adverse events occurred during the 5 year follow-up. None of the dose groups was associated with an
increased risk of starting insulin treatment compared with the placebo group. The use of oral hypoglycaemic agents did not
differ between the dose groups. After 5 years, fasting C-peptide levels declined in the placebo group (−0.24; 95% CI −0.41
to −0.07 log10 nmol/l; p = 0.01) and the 500 μg dose group (−0.37; 95% CI −0.57 to −0.17 log10 nmol/l; p = 0.003), but not in the 4 μg (−0.10; 95% CI −0.28 to 0.07 log10 nmol/l; p = 0.20), 20 μg (0.04; 95% CI −0.12 to 0.19 log10 nmol/l; p = 0.58) and 100 μg (0.00; 95% CI −0.20 to −0.20 log10 nmol/l; p = 0.98) dose groups.
Conclusions/interpretation The primary outcome of safety was achieved, since no severe study-related adverse events occurred.
Trial registration Because the study was initiated before 1 July 2005, the protocol was not registered in a registry.
Funding This trial was funded by the National Institutes of Health (grant numbers DK26190 and DK53004), the Swedish Research Council
(grant number 72X-14064) and Diamyd Therapeutics (Stockholm, Sweden).
Electronic supplementary material The online version of this article (doi:) contains supplementary material, which is available to authorised users. 相似文献